What Dexak Treats: Main Uses and Benefits

Dexketoprofen is relevant for easing symptoms related to acute pain, commonly used when short-term symptomatic assistance is needed in situations involving distressing symptoms. The substance is relevant for easing symptoms related to moderate to severe acute pain.

The medication is commonly used across conditions presenting with acute episodes, specifically targeting symptoms related to physical discomfort from acute musculoskeletal injuries, such as sprains, strains, and low back pain. It is also relevant when supportive symptom management is appropriate for post-traumatic pain, where symptoms may intensify temporarily, contributing to improved comfort during periods of heightened symptoms.

Management of Episodic Pain and Systemic Symptoms

Dexak is applicable in conditions marked by episodic or fluctuating symptom patterns, and is considered relevant for easing symptoms related to primary dysmenorrhoea (menstrual cramps) and may assist with symptoms related to acute migraine attacks. Additionally, it assists with managing symptoms related to systemic imbalance, such as fever, and is relevant for easing symptoms associated with heightened physiological activity.

It is applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Acute Pain Dexak is applied when supportive symptom management is appropriate for short-term, intense discomfort, and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. Summary of Product Characteristics

The population eligibility for Dexak (Dexketoprofen) is strictly defined by regulatory documents, distinguishing between permitted adult use and several absolute contraindications and restrictions. The medicine must not be used by patients with known hypersensitivity to the drug, any other Non-Steroidal Anti-Inflammatory Drug (NSAID), or aspirin. It is absolutely prohibited for individuals with active peptic ulcer, gastrointestinal bleeding, severe heart failure, severe renal impairment, or severe hepatic impairment. Use is also strictly contraindicated during the third trimester of pregnancy and while breastfeeding. For the pediatric population (children and adolescents), Dexak is not recommended as its safety and efficacy have not been established. Use in older adults requires enhanced caution and close monitoring due to an increased risk of serious adverse reactions. Additionally, individuals with mild-to-moderate renal or hepatic impairment, or those in the first two trimesters of pregnancy, qualify only for conditional use under close medical oversight and typically with reduced maximum daily doses.

Interactions with other medicines and products

Official regulatory documentation identifies several interaction patterns for Dexketoprofen, primarily concerning heightened toxicity risks and additive pharmacodynamic effects. Co-administration is strictly contraindicated with several specific substances.

Contraindicated and High-Risk Combinations

Combinations classified as strictly prohibited risk severe outcomes such as major gastrointestinal hemorrhage, interference with haemostasis, or rapid increases in the plasma concentration of the interacting medicine (e.g., Lithium and high-dose Methotrexate) leading to toxicity. The combination with Warfarin is prohibited due to interference with blood clotting.

Caution Required for Exposure and Renal Effects

Interaction with medicines like ACE Inhibitors, Angiotensin II Antagonists (ARBs), and Diuretics is associated with an increased risk of nephrotoxicity and may reduce their blood pressure-lowering efficacy. Administration with food is documented to delay the time to peak plasma concentration (tmax) and reduce the peak concentration (Cmax). Additionally, co-administration with Alcohol is noted to increase the risk of gastrointestinal bleeding. Close monitoring is specified for combinations involving Digoxin and low-dose Methotrexate (< 15 mg/week) due to increased exposure risk.

Molecular Action: Inhibiting the COX Enzymes

Dexak (dexketoprofen) acts as a non-selective competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular interaction modifies the activity of the body's enzyme-mediated signaling system, initiating the mechanism that leads to the drug's resulting physiological consequences.

Mechanistic Cascade: Modulating Prostaglandin Production

The primary biochemical result of COX inhibition is the reduction of prostaglandin synthesis pathway activity. Prostaglandins are chemical mediators involved in inflammation; reducing their formation results in reduced signaling by specific mediators in the local tissue environment and within the central nervous system.

️ Physiological Effect: Modifying Signaling and Thermoregulation

Modulation of this pathway results in specific physiological changes: it reduces the sensitization threshold of peripheral nerve endings, and centrally, it modifies the activity of the body’s central temperature set point by limiting the release of specific prostaglandin signals in the hypothalamus.

Dexketoprofen is authorized for administration via two primary pathways: oral (film-coated tablets or granules for solution) and parenteral (intramuscular or intravenous injection/infusion). The use of this medication is limited to the short-term treatment of acute symptoms, spanning only the necessary symptomatic period.

The standard oral regimen involves single doses of 12.5 mg taken at 4-to-6-hour intervals, or 25 mg doses administered every 8 hours. The total dose taken within a 24-hour period must not exceed 75 mg. To facilitate rapid absorption during acute episodes, the oral form is taken at least 30 minutes before meals. Parenteral administration is typically reserved for situations where oral intake is not feasible, using a 50 mg injection every 8 to 12 hours, with a maximum daily limit of 150 mg.

Dosing protocols mandate adjustments for specific populations. Older adults, as well as individuals with mild hepatic or mild renal impairment, must begin treatment with a reduced total daily dose, generally 50 mg, before any increase can be considered. Procedural protocols for both routes require the use of the lowest effective dose for the shortest possible duration. Intravenous administration procedures specify that the solution must be diluted and protected from natural daylight during the 10-to-30-minute infusion process.

Research Evidence: Overview of Clinical Studies

Evidence for Use in Post-operative Acute Pain

Research has frequently focused on Dexketoprofen as part of studies for symptom management following medical procedures, such as dental or major orthopedic surgery. These investigations primarily used short-term, randomized controlled trials (RCTs). Studies monitored various outcomes related to physical discomfort, including changes in pain intensity scores and the requirement for supplemental pain relief medication.

Findings describe patterns observed in the studies during the short follow-up period, often comparing observations to a placebo or to other medicines studied for pain relief. The results apply only to the specific populations studied, and data for certain high-risk groups or those with pre-existing conditions remain insufficient.

Evidence for Use in Acute Musculoskeletal Pain

For acute musculoskeletal discomfort, such as low back pain or soft-tissue injuries (strains and sprains), the evidence base includes both RCTs and observational studies. Research examined the medicine's application in conditions associated with acute or disruptive episodes, evaluating outcomes related to physical discomfort.

Findings indicate patterns where pain intensity measurements changed during the study period, typically less than one week. Since the conditions studied are temporary, follow-up durations were limited to the acute phase. This means there is limited information for long-term outcomes or how the medicine was observed to relate to symptom resolution beyond the initial period of heightened symptom activity.

Areas of Research Uncertainty and Gaps

Long-term effects are not fully established, as follow-up durations were limited to acute episodes (usually less than a week). Data for certain groups remain insufficient, especially for children, pregnant populations, and adults with complex or multiple co-existing medical conditions. The research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Common questions about Dexak (FAQ)

Q: How long does it usually take for Dexak to start working?

According to official product information, the pain-relieving effects generally onset within 15 to 30 minutes after taking the oral dose. The medication is absorbed relatively quickly when used for acute pain symptoms.

Q: How long does the effect of one Dexak tablet usually last?

Regulatory documents indicate that the analgesic effect typically persists for 4 to 6 hours. This duration is consistent with the recommended intervals between single doses for the management of acute symptoms.

Q: Is Dexak considered a strong pain reliever?

Official drug documentation indicates that Dexak is indicated for the treatment of mild to moderate acute pain. Its purpose is to provide effective relief for discomfort within this range of intensity.

Q: Can Dexak be taken for tension headaches?

Dexak is indicated for the symptomatic relief of mild to moderate acute pain. The official labeling does not restrict its use for common types of acute pain, such as tension headaches.

Q: Why do some people take Dexak for period pain?

Official drug documentation explicitly states that Dexak is used for the treatment of mild to moderate pain, which includes painful periods (dysmenorrhoea). This use is based on the drug’s mechanism of reducing inflammatory mediators involved in this type of pain.

Q: What is the main difference between Dexak and other common painkillers?

Regulatory documents note that Dexketoprofen is the single active S-enantiomer of a related NSAID (ketoprofen). This focused composition allows it to achieve its therapeutic effect at a lower dose and may contribute to its faster onset of absorption compared to the full racemic drug.

Q: What is the purpose of taking Dexak for conditions like rheumatoid arthritis?

The medicine is strictly authorized for the short-term treatment of acute symptoms (pain and inflammation). For chronic conditions like rheumatoid arthritis, it would be used only to manage acute flare-ups or temporary increases in pain.

Q: Can Dexak be taken if I have a sensitive stomach?

Official warnings emphasize that Dexak is contraindicated if a patient has an active peptic ulcer, stomach or bowel bleeding, or chronic digestive problems. Regulatory requirements specify the need for enhanced caution when considering use due to the risk of gastrointestinal side effects.

Q: Is it common to feel sleepy after taking Dexak?

According to regulatory documents, sleepiness is listed as an uncommon side effect, potentially affecting up to 1 in 100 people. Other central nervous system effects like dizziness or headache are also noted.

Q: What happens if I miss a dose of Dexak?

Official guidance describes a procedure for a missed dose: it may be taken as soon as possible unless the next scheduled dose is near. Furthermore, official regulatory instructions strictly prohibit taking a double dose to compensate for a missed one.

Q: Can people who drive heavy machinery take Dexak?

The product may slightly affect the ability to drive or use machines due to the possibility of side effects like dizziness or drowsiness. The official label specifies that driving or operating machinery is not recommended if these effects are experienced.

Q: What are the signs of an allergic reaction to Dexak?

Signs of a severe allergic reaction (hypersensitivity) may include skin rash, swelling of the face, lips, or throat (angioedema), or breathlessness due to narrowing of the airways (bronchospasm). These are listed as very rare but serious adverse effects.

Q: Is there a link between Dexak and changes in mood?

The official side effect categories list nervousness and disturbed sleep (insomnia) as uncommon effects on the nervous system or psychiatric state. Official documentation highlights these potential effects.

Q: Are there any reports about Dexak causing temporary vision changes?

Yes, official documentation includes reports of less common or rare visual side effects. These include temporary blurred vision and disturbed colour perception.

Q: Is Dexak addictive?

Dexak belongs to the pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This class of medicine is primarily used for pain relief and inflammation and is not associated with dependence or addiction.

Q: Can Dexak be taken if I have asthma?

No, official regulatory documents state that Dexak is contraindicated if a patient has asthma or has suffered asthma attacks, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

Q: Is there a documented risk of Dexak causing tinnitus (ringing in the ears)?

Yes, regulatory documents list tinnitus (ringing in the ears) as an infrequent or uncommon adverse effect associated with this medication.

Q: Is Dexak metabolized through the liver?

Yes, official pharmacokinetic information confirms that metabolism of the active substance occurs primarily in the liver. This is the basis for regulatory instructions that require caution and dose adjustment for patients with liver impairment.

Q: Can Dexak cause dehydration or affect fluid balance?

Regulatory documents note that the drug can cause fluid retention and peripheral swelling (oedema). Regulatory documents specify that use requires caution in individuals who are dehydrated or are concurrently using diuretics.

Q: Does Dexak interact with common cold or flu medicines?

Official warnings strictly contraindicate the use of Dexak with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). NSAIDs are common active ingredients in many over-the-counter cold and flu preparations.

Q: Is there a generic version of Dexak?

The active ingredient is dexketoprofen trometamol. In many countries, medicines containing this same active substance are available under different brand names, not just Dexak.

Storage and Disposal of Dexak (Dexketoprofen) Film-Coated Tablets

The storage requirements for Dexak are dependent on the packaging. Tablets in a PVC-aluminium blister must not be stored above 30 °C. For tablets in Aclar-aluminium or aluminium-aluminium blisters, no special temperature conditions are required. In all cases, the product must be kept in the original package or outer carton to protect from light.

All Dexak tablets must be stored out of the sight and reach of children.

Disposal

Any unused or expired Dexak must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine must not be disposed of via wastewater or mixed with regular household waste.